Bipolar Depression, Bipolar Disorder, Depressive Disorder
Conditions
Brief summary
This is an observational (non-interventional) prospective study, carried out in drug-naïve outpatients who start a treatment with escitalopram, fluoxetine, sertraline or quetiapine. Five blood samples are collected (i.e. before initiating the drug, and then after 1, 2, 4 and 8 weeks of treatment). It does not affect the choice or the treatment dose. The primary objective of this study is to measure the association between the EDIT-B® editing signature and response to pharmacological treatment in drug-naïve patients. Results of this research could provide an aid to early diagnosis, optimize pharmacological treatment and guide clinical practice towards individualized treatment.
Interventions
None listed
Sponsors
Les Toises - Psychiatry and Psychotherapy Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult drug-naïve outpatients suffering from depression and/or bipolar disorders who start a pharmacological treatment with escitalopram, fluoxetine, sertraline or quetiapine and who gave his written informed consent to participate in the present study.
Exclusion criteria
* Any patient without capacity of discernment or with harmful use of psychoactive substances
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| psychiatric symptomatology | At baseline, 1,2,4,8 weeks | self- and hetero-questionnaire psychiatric scales |
| EDIT-B profiling | At baseline, 1,2,4,8 weeks | Measurement of RNA editing over time |
Countries
Switzerland
Contacts
Primary ContactAurélie Reymond-Delacrétaz, PhD
Outcome results
None listed